Literature DB >> 24264312

The expression of BTG1 is downregulated in NSCLC and possibly associated with tumor metastasis.

G G Sun1, Y F Lu, Y J Cheng, W N Hu.   

Abstract

This study aimed to analyze the expression, clinical significance of B cell translocation gene 1 (BTG1) in nonsmall cell lung cancer (NSCLC) and the biological effect in its cell line by BTG1 overexpression. Immunohistochemistry and western blot were used to analyze BTG1 protein expression in 82 cases of NSCLC and 38 cases of normal tissues to study the relationship between BTG1 expression and clinical factors. Recombinant lentiviral vector was constructed to overexpress EMP-1 and then infect NSCLC H1299 cell line. Quantitative real-time RT-PCR and western blot were used to detect the mRNA level and protein of BTG1. 3-[4,5-dimethylthiazol -2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay, cell apoptosis, cell cycles, and migration and invasion assays were also conducted as to the influence of the upregulated expression of BTG1 that might be found on H1299 cells biological effect. The level of BTG1 protein expression was found to be significantly lower in NSCLC tissue than normal tissues (P < 0.05). Decreased expression of BTG1 was significantly correlated with lymph node metastasis, clinic stage, and histological grade of patients with NSCLC (P < 0.05). Meanwhile, loss of BTG1 expression correlated significantly with poor overall survival time by Kaplan-Meier analysis (P < 0.05). The result of biological function show that H1299 cell transfected BTG1 had a lower survival fraction; higher percentage of the G0/G1 phases; higher cell apoptosis; significant decrease in migration and invasion; and lower CyclinD1, Bcl-2, and MMP-9 protein expression compared with H1299 cell untransfected BTG1 (P < 0.05). BTG1 expression decreased in NSCLC and correlated significantly with lymph node metastasis; clinical stage; histological grade; poor overall survival; cell proliferation; cell cycles; cell apoptosis; and migration and invasion in NSCLC cell by regulating CyclinD1, Bcl-2, and MMP-9 protein expression, suggesting that BTG1 may play important roles as a negative regulator to NSCLC cell.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24264312     DOI: 10.1007/s13277-013-1379-6

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  20 in total

1.  BTG gene expression in the p53-dependent and -independent cellular response to DNA damage.

Authors:  U Cortes; C Moyret-Lalle; N Falette; C Duriez; F E Ghissassi; C Barnas; A P Morel; P Hainaut; J P Magaud; A Puisieux
Journal:  Mol Carcinog       Date:  2000-02       Impact factor: 4.784

2.  Apoptosis. Life and death decisions.

Authors:  Donald W Nicholson; Nancy A Thornberry
Journal:  Science       Date:  2003-01-10       Impact factor: 47.728

3.  B cell translocation gene 1 contributes to antisense Bcl-2-mediated apoptosis in breast cancer cells.

Authors:  Rita Nahta; Linda X H Yuan; Derek J Fiterman; Li Zhang; W Fraser Symmans; Naoto T Ueno; Francisco J Esteva
Journal:  Mol Cancer Ther       Date:  2006-06       Impact factor: 6.261

Review 4.  Stromal effects on mammary gland development and breast cancer.

Authors:  Bryony S Wiseman; Zena Werb
Journal:  Science       Date:  2002-05-10       Impact factor: 47.728

5.  Prognostic value of bcl-2 expression among women with breast cancer in Libya.

Authors:  Eramah Ermiah; Abdelbaset Buhmeida; Ben Romdhane Khaled; Fathi Abdalla; Nada Salem; Seppo Pyrhönen; Yrjö Collan
Journal:  Tumour Biol       Date:  2013-02-16

Review 6.  The gene PC3(TIS21/BTG2), prototype member of the PC3/BTG/TOB family: regulator in control of cell growth, differentiation, and DNA repair?

Authors:  F Tirone
Journal:  J Cell Physiol       Date:  2001-05       Impact factor: 6.384

Review 7.  The mammalian anti-proliferative BTG/Tob protein family.

Authors:  G Sebastiaan Winkler
Journal:  J Cell Physiol       Date:  2010-01       Impact factor: 6.384

Review 8.  Nuclear factor-kappa B and cancer: its role in prevention and therapy.

Authors:  Alok C Bharti; Bharat B Aggarwal
Journal:  Biochem Pharmacol       Date:  2002-09       Impact factor: 5.858

9.  Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family.

Authors:  A Koff; F Cross; A Fisher; J Schumacher; K Leguellec; M Philippe; J M Roberts
Journal:  Cell       Date:  1991-09-20       Impact factor: 41.582

10.  BTG1, a member of a new family of antiproliferative genes.

Authors:  J P Rouault; R Rimokh; C Tessa; G Paranhos; M Ffrench; L Duret; M Garoccio; D Germain; J Samarut; J P Magaud
Journal:  EMBO J       Date:  1992-04       Impact factor: 11.598

View more
  14 in total

1.  Identification of BTG1 Status in Solid Cancer for Future Researches Using a System Review and Meta-analysis.

Authors:  Xiu-Qiong Chen; Fan-Qiao Meng; Hua Xiong; Ya-Li Wang; Wen-Hua Tang; Yan-Mei Zou
Journal:  Curr Med Sci       Date:  2020-03-13

Review 2.  Recent advances in the molecular diagnostics of gastric cancer.

Authors:  Mitsuro Kanda; Yasuhiro Kodera
Journal:  World J Gastroenterol       Date:  2015-09-14       Impact factor: 5.742

3.  BTG1 underexpression is an independent prognostic marker in esophageal squamous cell carcinoma.

Authors:  G G Sun; Y D Wang; Y J Cheng; W N Hu
Journal:  Tumour Biol       Date:  2014-06-27

4.  BTG1 potentiates apoptosis and suppresses proliferation in renal cell carcinoma by interacting with PRMT1.

Authors:  Chunhui Liu; Tao Tao; Bin Xu; Kai Lu; Lei Zhang; Liang Jiang; Shuqiu Chen; Dachuang Liu; Xiaowen Zhang; Nihao Cao; Ming Chen
Journal:  Oncol Lett       Date:  2015-05-29       Impact factor: 2.967

5.  BTG1 expression correlates with pathogenesis, aggressive behaviors and prognosis of gastric cancer: a potential target for gene therapy.

Authors:  Hua-chuan Zheng; Jing Li; Dao-fu Shen; Xue-feng Yang; Shuang Zhao; Ya-zhou Wu; Yasuo Takano; Hong-zhi Sun; Rong-jian Su; Jun-sheng Luo; Wen-feng Gou
Journal:  Oncotarget       Date:  2015-08-14

6.  B-cell translocation gene 1 is downregulated by promoter methylation in ovarian carcinoma.

Authors:  Ji-Ye Kim; Sung-Im Do; Go Eun Bae; Hyun-Soo Kim
Journal:  J Cancer       Date:  2017-08-22       Impact factor: 4.207

7.  TOB1-AS1 suppresses non-small cell lung cancer cell migration and invasion through a ceRNA network.

Authors:  Wen-Ji Shangguan; Hai-Tao Liu; Zu-Jun Que; Fang-Fang Qian; Ling-Shuang Liu; Jian-Hui Tian
Journal:  Exp Ther Med       Date:  2019-10-15       Impact factor: 2.447

8.  Tumor suppressor BTG1 promotes PRMT1-mediated ATF4 function in response to cellular stress.

Authors:  Laurensia Yuniati; Laurens T van der Meer; Esther Tijchon; Dorette van Ingen Schenau; Liesbeth van Emst; Marloes Levers; Sander A L Palit; Caroline Rodenbach; Geert Poelmans; Peter M Hoogerbrugge; Jixiu Shan; Michael S Kilberg; Blanca Scheijen; Frank N van Leeuwen
Journal:  Oncotarget       Date:  2016-01-19

Review 9.  Breast Cancer-Derived Extracellular Vesicles: Characterization and Contribution to the Metastatic Phenotype.

Authors:  Toni M Green; Mary L Alpaugh; Sanford H Barsky; Germana Rappa; Aurelio Lorico
Journal:  Biomed Res Int       Date:  2015-10-27       Impact factor: 3.411

10.  BTG1 might be employed as a biomarker for carcinogenesis and a target for gene therapy in colorectal cancers.

Authors:  Shuang Zhao; Shu-Rui Chen; Xue-Feng Yang; Dao-Fu Shen; Yasuo Takano; Rong-Jian Su; Hua-Chuan Zheng
Journal:  Oncotarget       Date:  2017-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.